BRISTOL MYERS SQUIBB CO
Tremor tracks 110 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Sep 9, 2026+2.6
Trials
- BMYBristol-Myers Squibb13Calm
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Running, no new patientsPhase 234 patientsMain results: Oct 31, 2025 - BMYCelgene13Calm
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Running, no new patientsPhase 379 patientsMain results: Aug 11, 2025 - BMYBristol-Myers Squibb13Calm
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
FinishedPhase 1/224 patientsMain results: Sep 1, 2025 - BMYBristol-Myers Squibb3Calm
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Signing up patientsPhase 31,000 patientsMain results: Jul 30, 2030 - BMYBristol-Myers Squibb3Calm
Pan Tumor Rollover Study
Signing up patientsPhase 21,500 patientsMain results: Aug 25, 2029 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Signing up patientsPhase 2/3690 patientsMain results: Nov 8, 2030 - BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb Company3Calm
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Signing up patientsPhase 265 patientsMain results: Jan 9, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Signing up patientsPhase 3850 patientsMain results: Sep 18, 2030 - BMYBristol-Myers Squibb3Calm
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Signing up patientsPhase 2254 patientsMain results: Aug 15, 2028 - BMYBristol-Myers Squibb3Calm
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
FinishedPhase 31,314 patientsMain results: Aug 30, 2024 - BMYCelgene3Calm
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Signing up patientsPhase 2/31,541 patientsMain results: May 29, 2043 - BMYMirati Therapeutics Inc.3Calm
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Signing up patientsPhase 2/3626 patientsMain results: Oct 31, 2028 - BMYCelgene3Calm
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Signing up patientsPhase 3810 patientsMain results: Jan 10, 2027 - BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb Company3Calm
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Signing up patientsPhase 3440 patientsMain results: Dec 30, 2027 - BMYMirati Therapeutics Inc.3Calm
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Signing up patientsPhase 2170 patientsMain results: Feb 16, 2028 - BMYMirati Therapeutics Inc.3Calm
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Signing up patientsPhase 3630 patientsMain results: Sep 7, 2029 - BMYBristol-Myers Squibb3Calm
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Signing up patientsPhase 3850 patientsMain results: Dec 30, 2031 - BMYBristol-Myers Squibb3Calm
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Signing up patientsPhase 1/2460 patientsMain results: Oct 28, 2027 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Signing up patientsPhase 1/2198 patientsMain results: Oct 15, 2029 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Signing up patientsPhase 3750 patientsMain results: Oct 14, 2031 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Signing up patientsPhase 2/3990 patientsMain results: Feb 2, 2030 - BMYBristol-Myers Squibb3Calm
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Signing up patientsPhase 2160 patientsMain results: Sep 15, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Signing up patientsPhase 2/3590 patientsMain results: Aug 12, 2031 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Signing up patientsPhase 1/2474 patientsMain results: Nov 28, 2029 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2286 patientsMain results: Jan 4, 2029 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
FinishedPhase 1/282 patientsMain results: Jul 5, 2025 - BMYBristol-Myers Squibb3Calm
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Not started yetPhase 280 patientsMain results: Mar 15, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Signing up patientsPhase 3530 patientsMain results: Aug 17, 2027 - BMYBristol-Myers Squibb3Calm
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Signing up patientsPhase 2/3500 patientsMain results: Dec 15, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Running, no new patientsPhase 1/283 patientsMain results: Aug 11, 2026 - BMYJuno Therapeutics, Inc., a Bristol-Myers Squibb Company3Calm
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Signing up patientsPhase 2230 patientsMain results: Jul 31, 2026 - BMYCelgene3Calm
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Running, no new patientsPhase 3960 patientsMain results: Sep 12, 2027 - BMYMirati Therapeutics Inc.3Calm
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Running, no new patientsPhase 3461 patientsMain results: Jan 16, 2026 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Running, no new patientsPhase 3606 patientsMain results: Sep 28, 2026 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2416 patientsMain results: Feb 26, 2031 - BMYBristol-Myers Squibb3Calm
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
Running, no new patientsPhase 3681 patientsMain results: Jul 29, 2025 - BMYBristol-Myers Squibb3Calm
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Running, no new patientsPhase 3190 patientsMain results: Feb 16, 2027 - BMYBristol-Myers Squibb3Calm
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Signing up patientsPhase 2182 patientsMain results: Dec 29, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Running, no new patientsPhase 31,230 patientsMain results: Mar 15, 2029 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Running, no new patientsPhase 2100 patientsMain results: Apr 10, 2025 - BMYBristol-Myers Squibb3Calm
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Signing up patientsPhase 1/2240 patientsMain results: Apr 23, 2029 - BMYBristol-Myers Squibb3Calm
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
FinishedPhase 3855 patientsMain results: Feb 16, 2026 - BMYCelgene3Calm
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Signing up patientsPhase 1/262 patientsMain results: May 31, 2027 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Running, no new patientsPhase 1/2360 patientsMain results: Sep 5, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Running, no new patientsPhase 3461 patientsMain results: Jul 26, 2023 - BMYBristol-Myers Squibb3Calm
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Running, no new patientsPhase 3579 patientsMain results: Aug 4, 2025 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
FinishedPhase 3732 patientsMain results: Jul 9, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
Running, no new patientsPhase 3839 patientsMain results: Aug 28, 2024 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/21,109 patientsMain results: Aug 31, 2031 - BMYMirati Therapeutics Inc.3Calm
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Running, no new patientsPhase 2200 patientsMain results: Oct 30, 2026 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
FinishedPhase 1/268 patientsMain results: Aug 22, 2024 - BMYBristol-Myers Squibb3Calm
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2540 patientsMain results: Jul 31, 2028 - BMYMirati Therapeutics Inc.3Calm
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Running, no new patientsPhase 3453 patientsMain results: Dec 30, 2023 - BMYBristol-Myers Squibb3Calm
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Signing up patientsPhase 2/3600 patientsMain results: Mar 13, 2028 - BMYBristol-Myers Squibb3Calm
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Running, no new patientsPhase 3790 patientsMain results: Jun 28, 2022 - BMYMirati Therapeutics Inc.3Calm
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
FinishedPhase 2/349 patientsMain results: Apr 21, 2025 - BMYCelgene3Calm
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Running, no new patientsPhase 295 patientsMain results: Jun 19, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Running, no new patientsPhase 3545 patientsMain results: May 27, 2026 - BMYMirati Therapeutics Inc.3Calm
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Running, no new patientsPhase 1/2731 patientsMain results: Jun 23, 2026 - BMYBristol-Myers Squibb3Calm
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Signing up patientsPhase 2/3470 patientsMain results: Jan 26, 2029 - BMYCelgene3Calm
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Running, no new patientsPhase 3313 patientsMain results: May 26, 2025 - BMYJuno Therapeutics, a Subsidiary of Celgene3Calm
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Running, no new patientsPhase 1/2320 patientsMain results: Nov 26, 2027 - BMYCelgene3Calm
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Running, no new patientsPhase 3850 patientsMain results: Aug 9, 2027 - BMYCelgene3Calm
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Signing up patientsPhase 3665 patientsMain results: May 12, 2028 - BMYMirati Therapeutics Inc.3Calm
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Running, no new patientsPhase 290 patientsMain results: Sep 30, 2026 - BMYCelgene3Calm
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
FinishedPhase 3386 patientsMain results: Apr 13, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
FinishedPhase 2468 patientsMain results: Jan 11, 2024 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
FinishedPhase 2135 patientsMain results: May 22, 2025 - BMYCelgene3Calm
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
FinishedPhase 2186 patientsMain results: Apr 30, 2025 - BMYBristol-Myers Squibb3Calm
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Running, no new patientsPhase 2/3470 patientsMain results: May 3, 2029 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Signing up patientsPhase 1/2252 patientsMain results: Oct 13, 2028 - BMYCelgene3Calm
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Signing up patientsPhase 3400 patientsMain results: Apr 24, 2028 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 276 patientsMain results: Feb 5, 2027 - BMYBristol-Myers Squibb3Calm
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Running, no new patientsPhase 1/2216 patientsMain results: Aug 31, 2028 - BMYBristol-Myers Squibb3Calm
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
FinishedPhase 267 patientsMain results: Feb 23, 2026 - BMYBristol-Myers Squibb3Calm
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
FinishedPhase 1/21,482 patientsMain results: May 22, 2024 - BMYBristol-Myers Squibb3Calm
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
FinishedPhase 1/2229 patientsMain results: Feb 19, 2025 - BMYCelgene3Calm
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Running, no new patientsPhase 3939 patientsMain results: Nov 16, 2027 - BMYCelgene3Calm
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
FinishedPhase 25 patientsMain results: Apr 14, 2025 - BMYCelgene3Calm
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Running, no new patientsPhase 1/2466 patientsMain results: May 9, 2024 - BMYCelgene3Calm
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
FinishedPhase 2312 patientsMain results: Jan 15, 2026 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
FinishedPhase 1/2281 patientsMain results: Apr 26, 2024 - BMYCelgene3Calm
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Running, no new patientsPhase 1/2130 patientsMain results: Aug 2, 2018 - BMYCelgene3Calm
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Running, no new patientsPhase 1/2438 patientsMain results: Apr 7, 2027 - BMYBristol-Myers Squibb3Calm
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Running, no new patientsPhase 219 patientsMain results: Jan 27, 2025 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
FinishedPhase 2102 patientsMain results: Nov 12, 2025 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Running, no new patientsPhase 3437 patientsMain results: Mar 11, 2027 - BMYBristol-Myers Squibb3Calm
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
FinishedPhase 1/2219 patientsMain results: Aug 31, 2024 - BMYBristol-Myers Squibb3Calm
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer
FinishedPhase 1/2657 patientsMain results: Nov 12, 2024 - BMYBristol-Myers Squibb3Calm
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
FinishedPhase 1/244 patientsMain results: Aug 22, 2024 - BMYBristol-Myers Squibb3Calm
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
FinishedPhase 1/2325 patientsMain results: Nov 4, 2024 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
FinishedPhase 1/2356 patientsMain results: Nov 7, 2024 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
FinishedPhase 2385 patientsMain results: Oct 22, 2024 - BMYCelgene3Calm
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Running, no new patientsPhase 2276 patientsMain results: Sep 30, 2031 - BMYBristol-Myers Squibb3Calm
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
FinishedPhase 32,747 patientsMain results: Oct 25, 2024 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
FinishedPhase 1/237 patientsMain results: Jan 5, 2024 - BMYBristol-Myers Squibb3Calm
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Running, no new patientsPhase 2/3714 patientsMain results: Jan 25, 2021 - BMYBristol-Myers Squibb3Calm
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Signing up patientsPhase 1/2260 patientsMain results: Oct 12, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
FinishedPhase 3925 patientsMain results: Mar 22, 2024 - BMYCelgene3Calm
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
FinishedPhase 3503 patientsMain results: May 11, 2024 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Running, no new patientsPhase 1/2100 patientsMain results: Sep 30, 2026 - BMYCelgene3Calm
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
FinishedPhase 2149 patientsMain results: Dec 20, 2023 - BMYCelgene3Calm
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
FinishedPhase 31,030 patientsMain results: Apr 30, 2024 - BMYBristol-Myers Squibb3Calm
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
FinishedPhase 1/2101 patientsMain results: Jan 25, 2024 - BMYBristol-Myers Squibb3Calm
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
FinishedPhase 314 patientsMain results: Feb 8, 2024 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
FinishedPhase 272 patientsMain results: May 28, 2024 - BMYCelgene3Calm
A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
FinishedPhase 292 patientsMain results: Dec 19, 2023 - BMYCelgene3Calm
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
FinishedPhase 2113 patientsMain results: Dec 15, 2023 - BMYCelgene3Calm
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Running, no new patientsPhase 1/2424 patientsMain results: Nov 30, 2026 - BMYBristol-Myers Squibb3Calm
A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
FinishedPhase 326 patientsMain results: Dec 12, 2023
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
3 sales (3 not pre-planned) · 0 purchases
- Haller Julia ABoard member · Nov 5, 2026Sold 3,800 sharesabout $241 thousand · not pre-planned
- Massacesi CristianEVP,Chief Med Offr,Head of Dev · Sep 9, 2026Sold 6,249 sharesabout $403 thousand · not pre-planned
- Holzer Phil MSVP and Controller · Aug 25, 2026Sold 500 sharesabout $34 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.